| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -52,619 | - |
| Stock-based compensation expense | 8,158 | 5,425 |
| Depreciation and amortization expense | 2,530 | 1,678 |
| Impairment of long-lived assets | 0 | - |
| Noncash lease expense | 3,663 | 2,967 |
| Accretion of discount on marketable securities | 1,620 | 1,264 |
| Prepaid expenses and other current assets | -3,328 | -1,989 |
| Accounts payable | -573 | -463 |
| Accrued expenses and other liabilities | 769 | -388 |
| Operating lease liabilities | -5,802 | -4,633 |
| Deferred revenue | -21,662 | -13,509 |
| Net cash used in operating activities | -63,828 | -44,968 |
| Purchases of property and equipment | 50 | 50 |
| Purchases of marketable securities | 97,266 | 93,264 |
| Proceeds from maturities of marketable securities | 196,124 | 156,549 |
| Net cash provided by (used in) investing activities | 98,808 | 63,235 |
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions | 0 | 0 |
| Payments of public offering costs | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | 442 | 393 |
| Net cash provided by financing activities | 442 | 393 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 35,422 | 18,660 |
| Cash and cash equivalents at beginning of period | 57,162 | - |
| Cash and cash equivalents at end of period | 92,584 | - |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)